# A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment

> **NCT04059081** · PHASE2 · UNKNOWN · sponsor: **Deok-Hwan Yang** · enrollment: 31 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT04059081
- **Lead sponsor:** Deok-Hwan Yang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-09
- **Primary completion:** 2022-07-08
- **Final completion:** 2022-07-08
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2019-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04059081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04059081, "A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04059081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*